JP2016521707A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016521707A5 JP2016521707A5 JP2016517967A JP2016517967A JP2016521707A5 JP 2016521707 A5 JP2016521707 A5 JP 2016521707A5 JP 2016517967 A JP2016517967 A JP 2016517967A JP 2016517967 A JP2016517967 A JP 2016517967A JP 2016521707 A5 JP2016521707 A5 JP 2016521707A5
- Authority
- JP
- Japan
- Prior art keywords
- activatable antibody
- target
- seq
- activatable
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 22
- 108090000765 processed proteins & peptides Proteins 0.000 claims 17
- 150000001413 amino acids Chemical group 0.000 claims 12
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 229920001184 polypeptide Polymers 0.000 claims 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims 10
- 108091005804 Peptidases Proteins 0.000 claims 9
- 239000004365 Protease Substances 0.000 claims 9
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 9
- 239000012634 fragment Substances 0.000 claims 7
- 235000001014 amino acid Nutrition 0.000 claims 6
- 239000002131 composite material Substances 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- BLUGYPPOFIHFJS-UUFHNPECSA-N (2s)-n-[(2s)-1-[[(3r,4s,5s)-3-methoxy-1-[(2s)-2-[(1r,2r)-1-methoxy-2-methyl-3-oxo-3-[[(1s)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 BLUGYPPOFIHFJS-UUFHNPECSA-N 0.000 claims 5
- 102000004190 Enzymes Human genes 0.000 claims 4
- 108090000790 Enzymes Proteins 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 238000010494 dissociation reaction Methods 0.000 claims 4
- 230000005593 dissociations Effects 0.000 claims 4
- 125000006850 spacer group Chemical group 0.000 claims 4
- 239000000758 substrate Substances 0.000 claims 4
- 108010075254 C-Peptide Proteins 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- JARGNLJYKBUKSJ-KGZKBUQUSA-N (2r)-2-amino-5-[[(2r)-1-(carboxymethylamino)-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid;hydrobromide Chemical compound Br.OC(=O)[C@H](N)CCC(=O)N[C@H](CO)C(=O)NCC(O)=O JARGNLJYKBUKSJ-KGZKBUQUSA-N 0.000 claims 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 2
- 206010039509 Scab Diseases 0.000 claims 2
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims 2
- 239000003638 chemical reducing agent Substances 0.000 claims 2
- 108010044804 gamma-glutamyl-seryl-glycine Proteins 0.000 claims 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 2
- 108700026078 glutathione trisulfide Proteins 0.000 claims 2
- 230000000873 masking effect Effects 0.000 claims 2
- 108010093470 monomethyl auristatin E Proteins 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- WOWDZACBATWTAU-FEFUEGSOSA-N (2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-n-[(3r,4s,5s)-1-[(2s)-2-[(1r,2r)-3-[[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-n,3-dimethylbutanamide Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 WOWDZACBATWTAU-FEFUEGSOSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 108010024636 Glutathione Proteins 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical group OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 claims 1
- 108010044540 auristatin Proteins 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims 1
- 229930195731 calicheamicin Natural products 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000000536 complexating effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000001268 conjugating effect Effects 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 claims 1
- 229930188854 dolastatin Natural products 0.000 claims 1
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 claims 1
- 229960005501 duocarmycin Drugs 0.000 claims 1
- 229930184221 duocarmycin Natural products 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229960003180 glutathione Drugs 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002452 interceptive effect Effects 0.000 claims 1
- 231100000782 microtubule inhibitor Toxicity 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000003573 thiols Chemical class 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361830913P | 2013-06-04 | 2013-06-04 | |
| US61/830,913 | 2013-06-04 | ||
| US201361919935P | 2013-12-23 | 2013-12-23 | |
| US61/919,935 | 2013-12-23 | ||
| PCT/US2014/040931 WO2014197612A1 (en) | 2013-06-04 | 2014-06-04 | Compositions and methods for conjugating activatable antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020019517A Division JP2020079292A (ja) | 2013-06-04 | 2020-02-07 | 活性化可能抗体を結合するための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016521707A JP2016521707A (ja) | 2016-07-25 |
| JP2016521707A5 true JP2016521707A5 (cg-RX-API-DMAC7.html) | 2017-07-20 |
| JP6660294B2 JP6660294B2 (ja) | 2020-03-11 |
Family
ID=51023194
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016517967A Active JP6660294B2 (ja) | 2013-06-04 | 2014-06-04 | 活性化可能抗体を結合するための組成物及び方法 |
| JP2020019517A Pending JP2020079292A (ja) | 2013-06-04 | 2020-02-07 | 活性化可能抗体を結合するための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020019517A Pending JP2020079292A (ja) | 2013-06-04 | 2020-02-07 | 活性化可能抗体を結合するための組成物及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US9517276B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3003387A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6660294B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20160018579A (cg-RX-API-DMAC7.html) |
| CN (2) | CN105658240A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2014274982B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112015030514A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2913732A1 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2015156888A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014197612A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| AU2013251310B2 (en) | 2012-04-27 | 2018-02-15 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
| KR20160018579A (ko) * | 2013-06-04 | 2016-02-17 | 싸이톰스 테라퓨틱스, 인크. | 활성화가능 항체를 접합하기 위한 조성물 및 방법 |
| EP4067383A1 (en) * | 2013-07-25 | 2022-10-05 | Cytomx Therapeutics Inc. | Multispecific antibodies, multispecific activatable antibodies and methods of using the same |
| BR112016004242A8 (pt) | 2013-08-28 | 2018-06-12 | Stemcentrx Inc | Métodos para conjugação sítio-específica de anticorpos e composições |
| US9540440B2 (en) | 2013-10-30 | 2017-01-10 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
| CA2928671A1 (en) | 2013-11-06 | 2015-05-14 | Stemcentrx, Inc. | Novel anti-claudin antibodies and methods of use |
| US9737623B2 (en) | 2013-12-11 | 2017-08-22 | Cytomx Therapeutics, Inc. | Antibodies that bind activatable antibodies and methods of use thereof |
| EP3080607A4 (en) | 2013-12-12 | 2017-07-12 | AbbVie Stemcentrx LLC | Novel anti-dpep3 antibodies and methods of use |
| AU2015218633A1 (en) | 2014-02-21 | 2016-09-01 | Abbvie Stemcentrx Llc | Anti-DLL3 antibodies and drug conjugates for use in melanoma |
| AU2015292406B2 (en) | 2014-07-25 | 2021-03-11 | Cytomx Therapeutics, Inc | Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same |
| TW201617368A (zh) | 2014-09-05 | 2016-05-16 | 史坦森特瑞斯公司 | 新穎抗ｍｆｉ２抗體及使用方法 |
| EP3244907B1 (en) * | 2015-01-13 | 2020-02-19 | City of Hope | Ctla4-binding protein peptide-linker masks |
| MA41374A (fr) * | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| WO2016164370A1 (en) * | 2015-04-06 | 2016-10-13 | Ohio State Innovation Foundation | Egfr-directed car therapy for glioblastoma |
| ES2796698T3 (es) * | 2015-05-04 | 2020-11-30 | Cytomx Therapeutics Inc | Anticuerpos anti-CD166 activables y procedimientos de uso de los mismos |
| JP2018518972A (ja) * | 2015-06-26 | 2018-07-19 | ユニバーシティ オブ サザン カリフォルニア | 腫瘍特異的活性化のためのマスキングキメラ抗原受容体ｔ細胞 |
| CN106519037B (zh) * | 2015-09-11 | 2019-07-23 | 科济生物医药（上海）有限公司 | 可活化的嵌合受体 |
| FI3377103T4 (fi) | 2015-11-19 | 2025-04-16 | Revitope Limited | Funktionaalinen vasta-ainefragmenttikomplementointi kaksikomponenttiselle järjestelmälle epätoivottujen solujen uudelleenohjattua tappamista varten |
| CN105267982A (zh) * | 2015-11-20 | 2016-01-27 | 暨南大学 | 一种rhHER2抗体与MMAE偶联物及其制备方法与应用 |
| AU2017228293B2 (en) * | 2016-02-29 | 2023-05-25 | Regeneron Pharmaceuticals, Inc. | Rodents having a humanized Tmprss gene |
| US12128102B2 (en) | 2016-03-08 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| EP3454900A4 (en) * | 2016-05-09 | 2020-01-29 | Celgene Corporation | CD47 ANTIBODIES AND METHODS OF USE |
| CA3042276A1 (en) | 2016-12-09 | 2018-06-14 | Seattle Genetics, Inc. | Bivalent antibodies masked by coiled coils |
| EP3652210A1 (en) | 2017-07-14 | 2020-05-20 | CytomX Therapeutics, Inc. | Anti-cd166 antibodies and uses thereof |
| BR112020004543A2 (pt) | 2017-09-08 | 2020-09-08 | Maverick Therapeutics, Inc. | proteínas de ligação ativadas condicionalmente restritas |
| BR112020007309A2 (pt) | 2017-10-14 | 2020-09-29 | Cytomx Therapeutics, Inc. | anticorpos, anticorpos ativáveis, anticorpos biespecíficos e anticorpos ativáveis biespecíficos e métodos de uso dos mesmos |
| EP3769309A1 (en) | 2018-03-20 | 2021-01-27 | Cytomx Therapeutics Inc. | Systems and methods for quantitative pharmacological modeling of activatable antibody species in mammalian subjects |
| CN108484781B (zh) * | 2018-04-23 | 2021-05-04 | 深圳市国创纳米抗体技术有限公司 | 一种纳米抗体与铜绿假单胞菌外毒素的融合蛋白及应用 |
| IL278615B1 (en) | 2018-05-14 | 2025-10-01 | Werewolf Therapeutics Inc | Activatable interleukin 12 polypeptides and methods of using them |
| ES2955511T3 (es) | 2018-05-14 | 2023-12-04 | Werewolf Therapeutics Inc | Polipéptidos de interleucina 2 activables y métodos de uso de los mismos |
| WO2019241430A2 (en) * | 2018-06-12 | 2019-12-19 | Angiex, Inc. | Antibody-oligonucleotide conjugates |
| KR20210039395A (ko) | 2018-07-31 | 2021-04-09 | 암젠 인크 | 마스킹된 항체의 약제학적 제형 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| AU2019394972A1 (en) | 2018-12-06 | 2021-06-03 | Cytomx Therapeutics, Inc. | Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof |
| CN113423730B (zh) | 2019-02-15 | 2024-01-05 | 上海药明合联生物技术有限公司 | 用于制备具有改善的同质性的抗体-药物缀合物的方法 |
| US12109273B2 (en) | 2019-02-15 | 2024-10-08 | Wuxi Xdc Singapore Private Limited | Process for preparing antibody-drug conjugates with improved homogeneity |
| WO2020176672A1 (en) * | 2019-02-26 | 2020-09-03 | Cytomx Therapeutics, Inc. | Combined therapies of activatable immune checkpoint inhibitors and conjugated activatable antibodies |
| EP4592313A3 (en) | 2019-03-05 | 2025-11-19 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| EP3969035A4 (en) | 2019-05-14 | 2023-06-21 | Werewolf Therapeutics, Inc. | SEPARATION UNITS AND METHODS AND THEIR USE |
| EP4058471A1 (en) | 2019-11-14 | 2022-09-21 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| BR112022013223A2 (pt) * | 2020-01-06 | 2022-09-06 | Cytomx Therapeutics Inc | Compostos relacionados à auristatina, compostos conjugados de auristatina e métodos de uso dos mesmos |
| EP4132656A1 (en) | 2020-04-09 | 2023-02-15 | CytomX Therapeutics, Inc. | Compositions containing activatable antibodies |
| CN112285361B (zh) * | 2020-09-27 | 2023-12-05 | 中国人民解放军空军军医大学 | 排除抗-cd38单克隆抗体药物对抗人球蛋白检测干扰的试剂 |
| WO2022081541A1 (en) * | 2020-10-13 | 2022-04-21 | Chan Zuckerberg Biohub, Inc. | Compositions and methods involving antibody constructs |
| WO2023070353A1 (en) * | 2021-10-27 | 2023-05-04 | Adagene Pte. Ltd. | Anti-cd47 antibodies and methods of use thereof |
| JP2025524628A (ja) | 2022-07-12 | 2025-07-30 | シートムエックス セラピューティクス，インコーポレイテッド | Ｅｐｃａｍイムノコンジュゲート及びその使用 |
| CN120058950A (zh) * | 2023-11-28 | 2025-05-30 | 昆山新蕴达生物科技有限公司 | 抗adam9的抗体及其用途 |
| WO2025240659A2 (en) | 2024-05-14 | 2025-11-20 | Cytomx Therapeutics, Inc. | Activatable constructs, compositions and methods |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| EP0279862B1 (en) | 1986-08-28 | 1993-11-03 | Teijin Limited | Cytocidal antibody complex and process for its preparation |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| DE69329503T2 (de) | 1992-11-13 | 2001-05-03 | Idec Pharma Corp | Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
| WO2001091798A2 (en) * | 2000-06-01 | 2001-12-06 | Universite Catholique De Louvain | Tumor activated prodrug compounds |
| US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US20040109855A1 (en) | 2002-07-23 | 2004-06-10 | Herman Waldmann | Therapeutic antibodies with reduced side effect |
| EP2353611B1 (en) | 2002-07-31 | 2015-05-13 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| AU2003265866A1 (en) | 2002-09-03 | 2004-03-29 | Vit Lauermann | Targeted release |
| US8088387B2 (en) * | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| KR101520209B1 (ko) | 2003-11-06 | 2015-05-13 | 시애틀 지네틱스, 인크. | 리간드에 접합될 수 있는 모노메틸발린 화합물 |
| EP1725586B1 (en) * | 2004-03-02 | 2015-01-14 | Seattle Genetics, Inc. | Partially loaded antibodies and methods of their conjugation |
| ATE476994T1 (de) * | 2004-11-30 | 2010-08-15 | Curagen Corp | Antikörper gegen gpnmb und ihre verwendungen |
| CN101287498B (zh) * | 2005-06-20 | 2013-03-27 | Psma开发有限公司 | Psma抗体-药物缀合物 |
| EP2535346B1 (en) | 2005-08-31 | 2017-08-02 | The Regents of The University of California | Cellular libraries of peptide sequences (CLiPS) and methods of using the same |
| WO2007105027A1 (en) | 2006-03-10 | 2007-09-20 | Diatos | Anticancer drugs conjugated to antibody via an enzyme cleavable linker |
| WO2009014726A1 (en) | 2007-07-26 | 2009-01-29 | The Regents Of The University Of California | Methods for enhancing bacterial cell display of proteins and peptides |
| EP2190861A4 (en) * | 2007-08-22 | 2011-03-30 | Univ California | ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE |
| US20100189727A1 (en) | 2008-12-08 | 2010-07-29 | Tegopharm Corporation | Masking Ligands For Reversible Inhibition Of Multivalent Compounds |
| BRPI1006141B8 (pt) | 2009-01-12 | 2021-05-25 | Cytomx Therapeutics Llc | composições de anticorpo modificado, métodos para preparar e usar as mesmas |
| US9309325B2 (en) | 2009-05-07 | 2016-04-12 | The Regents Of The University Of California | Antibodies and methods of use thereof |
| EP2635310A2 (en) * | 2010-11-05 | 2013-09-11 | Rinat Neuroscience Corp. | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| KR101529810B1 (ko) | 2011-04-01 | 2015-06-26 | 와이어쓰 엘엘씨 | 항체-약물 접합체 |
| CN103826661B (zh) | 2011-04-21 | 2019-03-05 | 西雅图基因公司 | 新的结合剂-药物缀合物(adc)及其用途 |
| WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
| KR20140091040A (ko) * | 2011-11-11 | 2014-07-18 | 리나트 뉴로사이언스 코프. | Trop-2에 특이적인 항체 및 그의 용도 |
| EP2780039B9 (en) | 2011-11-17 | 2018-04-18 | Pfizer Inc | Cytotoxic peptides and antibody drug conjugates thereof |
| EP2818480B1 (en) * | 2012-02-24 | 2020-08-26 | Alteogen Inc. | Modified antibody in which motif comprising cysteine residue is bound, modified antibody-drug conjugate comprising the modified antibody, and production method for same |
| WO2013192546A1 (en) * | 2012-06-22 | 2013-12-27 | Cytomx Therapeutics, Inc. | Activatable antibodies having non-binding steric moieties and mehtods of using the same |
| KR20150037857A (ko) | 2012-06-22 | 2015-04-08 | 싸이톰스 테라퓨틱스, 인크. | 항-jagged 1/jagged 2 교차-반응성 항체, 활성화가능한 항-jagged 항체 및 이의 제조 방법 |
| WO2014004694A1 (en) * | 2012-06-26 | 2014-01-03 | Massachusetts Institute Of Technology | Reversible masking of pore-forming proteins for macromolecular delivery |
| US9487590B2 (en) * | 2012-09-25 | 2016-11-08 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind interleukin-6 receptor and methods of use thereof |
| IN2015DN02349A (cg-RX-API-DMAC7.html) * | 2012-10-24 | 2015-08-28 | Polytherics Ltd | |
| RU2015132436A (ru) | 2013-01-04 | 2017-02-09 | Сайтомкс Терапьютикс, Инк. | Способы обнаружения активности протеазы в биологических системах и композиции для их осуществления |
| KR20160018579A (ko) * | 2013-06-04 | 2016-02-17 | 싸이톰스 테라퓨틱스, 인크. | 활성화가능 항체를 접합하기 위한 조성물 및 방법 |
-
2014
- 2014-06-04 KR KR1020157036292A patent/KR20160018579A/ko not_active Ceased
- 2014-06-04 EP EP14733931.1A patent/EP3003387A1/en active Pending
- 2014-06-04 AU AU2014274982A patent/AU2014274982B2/en not_active Ceased
- 2014-06-04 CN CN201480043966.1A patent/CN105658240A/zh active Pending
- 2014-06-04 BR BR112015030514A patent/BR112015030514A2/pt not_active IP Right Cessation
- 2014-06-04 JP JP2016517967A patent/JP6660294B2/ja active Active
- 2014-06-04 CN CN202210873109.0A patent/CN116063479A/zh active Pending
- 2014-06-04 WO PCT/US2014/040931 patent/WO2014197612A1/en not_active Ceased
- 2014-06-04 CA CA2913732A patent/CA2913732A1/en not_active Abandoned
- 2014-06-04 US US14/296,207 patent/US9517276B2/en active Active
- 2014-06-04 RU RU2015156888A patent/RU2015156888A/ru not_active Application Discontinuation
-
2016
- 2016-11-22 US US15/359,100 patent/US20170072067A1/en not_active Abandoned
-
2020
- 2020-02-07 JP JP2020019517A patent/JP2020079292A/ja active Pending
- 2020-02-26 AU AU2020201405A patent/AU2020201405A1/en not_active Abandoned
-
2021
- 2021-04-09 US US17/227,004 patent/US11992528B2/en active Active
-
2024
- 2024-04-26 US US18/648,088 patent/US20250099606A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016521707A5 (cg-RX-API-DMAC7.html) | ||
| RU2015156888A (ru) | Композиции и методы конъюгирования активируемых антител | |
| JP2022046569A5 (cg-RX-API-DMAC7.html) | ||
| US11986535B2 (en) | Method of producing an immunoligand/payload conjugate | |
| JP2022064924A5 (cg-RX-API-DMAC7.html) | ||
| RU2016135239A (ru) | Субстраты матриптазы и u-активатора плазминогена и другие расщепляемые остатки и способы их применения | |
| JP2018504925A5 (cg-RX-API-DMAC7.html) | ||
| JP2016525551A5 (cg-RX-API-DMAC7.html) | ||
| JP2017509594A5 (cg-RX-API-DMAC7.html) | ||
| JP2018520092A5 (cg-RX-API-DMAC7.html) | ||
| RU2016106115A (ru) | Мультспецифические антитела, мультспецифические активируемые антитела и способы их применения | |
| JP2016538240A5 (cg-RX-API-DMAC7.html) | ||
| HRP20220631T1 (hr) | Supstrati koje mogu cijepati matrične metaloproteaze i serinske proteaze, te postupci njihove uporabe | |
| JP2015516813A5 (cg-RX-API-DMAC7.html) | ||
| JP2022065174A5 (cg-RX-API-DMAC7.html) | ||
| JP2017523176A5 (cg-RX-API-DMAC7.html) | ||
| RU2015100656A (ru) | Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения | |
| HRP20200721T1 (hr) | Aktivirajuća anti-cd166 antitijela i postupci njihove uporabe | |
| RU2015101803A (ru) | Перекрестно реактивные антитела к jagged 1/k jagged 2, активируемые антитела к jagged и способы их применения | |
| HRP20220172T1 (hr) | Protutijela protiv cd71 koja se mogu aktivirati, te postupci njihove uporabe | |
| JP2020500016A5 (cg-RX-API-DMAC7.html) | ||
| PE20060817A1 (es) | Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina | |
| JPWO2020118109A5 (cg-RX-API-DMAC7.html) | ||
| PE20071055A1 (es) | Anticuerpos anti mn | |
| IN2012DN02535A (cg-RX-API-DMAC7.html) |